lncRNA ACTA2-AS1 serves as a prognostic indicator of malignancy and adverse outcomes in triple-negative breast cancer, influencing tumor progression through the modulation of miR-532-5p [20]. This evidence concerns the gene ACTA2 and neoplasm.